Clinical Trial

Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

Study acronym: EPCOR+LONCA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-02; most recent amendment 2026-02-26.
Status change: Not Yet Recruiting → Recruiting 2025-12-16
Trial Details
NCT Number NCT06919939
Lead Sponsor University of Miami
Collaborators: ADC Therapeutics S.A., Genmab
Conditions Large B-cell Lymphoma, Relapse
Enrollment 26 participants
Start Date 2026-01-07
Primary Completion 2031-01-07 (estimated)
Study Completion 2031-01-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-02